SCHEMBL24160854

SCHEMBL24160854

CSc1nc(SC)c2ncc([C@@H]3O[C@H](COCc4ccccc4)[C@@H](OCc4ccccc4)[C@H]3C)n2n1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 1/20 0.39
▸ HTR1A P08908 1/20 0.37
▸ PTPN1 P18031 10/20 0.36
▸ CDC25B P30305 8/20 0.36
▸ BCHE P06276 1/20 0.35
▸ PTPN2 P17706 6/20 0.34
▸ PTPN6 P29350 4/20 0.34
▸ PTPN11 Q06124 4/20 0.34
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ TACR2 P21452 1/20 0.33
▸ GJB2 P29033 1/20 0.33
▸ SSTR1 P30872 1/20 0.33
▸ SSTR2 P30874 1/20 0.33
▸ SSTR4 P31391 1/20 0.33
▸ SSTR3 P32745 1/20 0.33
▸ SSTR5 P35346 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21078687 0.93 HTR1A (0.40) PDE2AHTR1APTPN1CDC25BBCHE
SCHEMBL21046783 0.93 HTR1A (0.40) PDE2AHTR1APTPN1CDC25BBCHE
SCHEMBL18788248 0.91 PDE2A (0.44) PDE2AHTR1APTPN1CDC25BBCHE
SCHEMBL21046350 0.83 PDE2A (0.43) PDE2AHTR1APTPN1CDC25BBCHE
SCHEMBL18788249 0.83 PDE2A (0.49) PDE2AHTR1APTPN1CDC25BBCHE
SCHEMBL18788241 0.81 PDE2A (0.42) PDE2AHTR1APTPN1CDC25BBCHE
SCHEMBL17106843 0.81 HTR1A (0.41) PDE2AHTR1APTPN1CDC25BBCHE
SCHEMBL17106842 0.81 HTR1A (0.41) PDE2AHTR1APTPN1CDC25BBCHE
SCHEMBL13648874 0.81 PDE2A (0.44) PDE2AHTR1APTPN1CDC25BBCHE
SCHEMBL12253797 0.80 PDE2A (0.33) PDE2AHTR1ABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3932931-A1 A NEBULIZER COMPRISING A PHARMACEUTICAL COMPOSITION COMPRISING 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT Gilead Sciences, Inc. (US) 2022-01-05 — — EP disclosed
Send feedback